These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15254025)

  • 41. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
    Paukner S; Hesse L; Prezelj A; Solmajer T; Urleb U
    Antimicrob Agents Chemother; 2009 Feb; 53(2):505-11. PubMed ID: 19075067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.
    Cha MK; Kang CI; Kim SH; Cho SY; Ha YE; Wi YM; Chung DR; Peck KR; Song JH;
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5834-7. PubMed ID: 26124174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterisation of a unique ceftazidime-hydrolysing beta-lactamase, TEM-E2.
    Payne DJ; Marriott MS; Amyes SG
    J Med Microbiol; 1990 Jun; 32(2):131-4. PubMed ID: 2192063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L; Verhaegen J; Wouters C; Vandenhoven G
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Study of in vitro activity of 3 cephalosporins and their combination with 2 beta-lactamase inhibitors against 4 enterobacteria strains producing extended spectrum beta-lactamase].
    Cattoen C; Duflos D; Bouillet L; Chatelain C; Mazars E
    Pathol Biol (Paris); 1997 May; 45(5):425-9. PubMed ID: 9296097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
    Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
    Pohlman JK; Knapp CC; Ludwig MD; Washington JA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):29-33. PubMed ID: 8950526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3.
    Poirel L; Gniadkowski M; Nordmann P
    J Antimicrob Chemother; 2002 Dec; 50(6):1031-4. PubMed ID: 12461028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interaction of beta-lactamase inhibitors with various beta-lactamases.
    Cullmann W
    Chemotherapy; 1990; 36(3):200-8. PubMed ID: 2159863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficiency of tazobactam as inhibitor of beta-lactamases, combined with piperacillin, against resistant strains to this penicillin].
    Roy C; Tirado M; Teruel D; Reig R; Ràfols M
    Med Clin (Barc); 1989 Mar; 92(10):371-4. PubMed ID: 2541285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals.
    Verbist L; Dhoore P
    Acta Clin Belg; 1995; 50(5):274-81. PubMed ID: 8533527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam.
    Kadima TA; Weiner JH
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2177-83. PubMed ID: 9333044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High rates of resistance to piperacillin/tazobactam among Escherichia coli and Klebsiella pneumoniae strains isolated in a Greek hospital.
    Tsakris A; Douboyas J; Tzouvelekis LS
    Diagn Microbiol Infect Dis; 1997 Sep; 29(1):39-41. PubMed ID: 9350414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants).
    Higashitani F; Nishida K; Hyodo A; Inoue M
    J Antibiot (Tokyo); 1995 Sep; 48(9):1027-33. PubMed ID: 7592048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins.
    McDougal LK; Thornsberry C
    J Clin Microbiol; 1986 May; 23(5):832-9. PubMed ID: 3011847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria.
    Farmer TH; Degnan BA; Payne DJ
    FEMS Microbiol Lett; 1999 Jul; 176(1):11-5. PubMed ID: 10418127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
    Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.
    Kitzis MD; Billot-Klein D; Goldstein FW; Williamson R; Tran Van Nhieu G; Carlet J; Acar JF; Gutmann L
    Antimicrob Agents Chemother; 1988 Jan; 32(1):9-14. PubMed ID: 2831817
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L; Dornbusch K; Hallander HO
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.